Author: Constance L. PercyPublisher:
ISBN:
Category : Tumors
Languages : en
Pages : 214
Book Description
Conversion of Neoplasms by Topography and Morphology from the International Classification of Diseases for Oncology (ICD-0) to Chapter II, Neoplasms, 9th Revision of the International Classification of Diseases, (ICD-9) 1975
Author: Constance L. PercyPublisher:
ISBN:
Category : Tumors
Languages : en
Pages : 214
Book Description
Conversion of Neoplasms by Topography and Morphology from the International Classification of Diseases for Oncology (ICD-0) to Chapter II, Neoplasms, 9th Revision of the International Classification of Diseases, (ICD-9) 1975
Author: Constance PercyPublisher:
ISBN:
Category : Nosology
Languages : en
Pages : 214
Book Description
Conversion of Neoplasms by Topography and Morphology
Author: Constance L. PercyPublisher:
ISBN:
Category : Tumors
Languages : en
Pages : 196
Book Description
Conversion of Neoplasms by Topography and Morphology from the International Classification of Diseases for Oncology (ICD-O) to Chapter II, Neoplasms, 9th Revision of the International Classification of Diseases, (ICD-9) 1975
Author: Constance L. PercyPublisher:
ISBN:
Category : Tumors
Languages : en
Pages : 214
Book Description
Conversion of Neoplasms by Topography and Morphology from the International Classification of Diseases for Oncology, Second Edition (ICD-O-2) to International Classification of Diseases for Oncology, (ICD-O) (first Edition and Field Trials)
Author: Constance L. PercyPublisher:
ISBN:
Category : Government publications
Languages : en
Pages : 196
Book Description
Epidemiologists, statisticians, oncologists as well as tumor registrars are interested in studying trends in both incidence and mortality. To be able to compare data from one period to another, it is essential that conversion tables be available so that all data is on the same code. The following conversion (comparison or equivalency) tables are from ICD-O-2 and back to the Field Trial editions and ICD-O-1. These tables are divided into Topography and Morphology. There is only one conversion table for the topography since ICD-O-1 and the Field Trials used the same Topography section. There is also one table for Morphology but with three columns: two for the Field Trials, 1988 and 1986 and one for ICD-O-1. The 1987 Field Trial was exactly the same as the 1988 Field Trial except for three terms in Hodgkin's disease: 9657, 9658 and 9659. In all probability this conversion will not be done on records, although a program on tape will be made on request. This conversion is made to help users see what the equivalent code number(s) was in a Field Trial or ICD-O-1.
Conversion of Neoplasms by Topography and Morphology from the International Classification of Diseases for Oncology, Second Edition (ICD-O-2) to the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10)
Author: Constance L. PercyPublisher:
ISBN:
Category : Tumors
Languages : en
Pages : 296
Book Description
Conversion of Neoplasms by Topography and Morphology from the International Classification of Diseases for Oncology, Second Edition (ICD-O-2) to International Classification of Diseases, 9th Revision (ICD-9) and the International Classification of Diseases, 9th Revision, Clinical Modification, Fourth Edition (ICD-9-CM) 4th Ed
Author: Constance L. PercyPublisher:
ISBN:
Category : Government publications
Languages : en
Pages : 320
Book Description
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), which is adapted from ICD-9, is used for coding morbidity in all hospitals, now in the 4th edition. It must be used for coding diagnoses which submit claims for third party payment. There are very slight differences between the two books in the Neoplasm Chapter, but the differences are shown in this book and are compiled in the last section of this book. The Topography Section of ICD-O-2 is based on the malignant neoplasms section, categories C00-C80 of the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10), so there is a close relationship between that and ICD-10. The Morphology Section of ICD-O-2 is a revised and expanded version of the Morphology Section of the ICD-O-1. This conversion has been prepared to help those who wish to compare or convert diagnoses coded according to ICD-O-2 with diagnoses coded according to the ICD-9-(CM). For example, a cancer registry may code its diagnoses by ICD-O-2, whereas the record room in the same hospital referring cases to the cancer registry may have used the ICD-9-(CM) to code its case material.
Conversion of Neoplasms by Topography and Morphology
Author: Constance L. PercyPublisher:
ISBN:
Category : Tumors
Languages : en
Pages : 229
Book Description
ICD-O-2 to ICD-10, Neoplasms, Conversion of Neoplasms by Topography and Morphology from the International Classification of Diseases for Oncology, Second Edition (ICD-O-2) to the International Statistical Classification Etc., (ICD-10), 1998
Author: Conversion of Neoplasms by Topography and Morphology from the International Classification of Diseases for Oncology (ICD-O), (first Edition and Field Trials) to International Classification of Diseases for Oncology, Second Edition (ICD-O-2)
Author: Valerie Van HoltenPublisher:
ISBN:
Category : Government publications
Languages : en
Pages : 212
Book Description
Epidemiologists, statisticians, oncologists as well as tumor registrars are interested in studying trends in both incidence and mortality. To be able to compare data from one period to another, it is essential that conversion tables be available. The following conversion (comparison or equivalency) tables are from ICD-O-1 and the Field Trial editions to ICD-0-2. These tables are divided into Topography and Morphology. There is only one conversion table for the topography since ICD-O-1 and the Field Trials used the same Topography section. However there are three tables for Morphology: one for ICD-O-1, one for the Field Trials, and one for special codes introduced by the Surveillance, Epidemiology, and End Results Program (SEER) of the National Cancer Institute (NCI).